SCHEMBL3378147

SCHEMBL3378147

Cn1cnc(S(=O)(=O)N(Cc2ccccc2)c2cccc(C(=O)N3CCOC(c4ccccc4)C3)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 2/20 0.40
PDE2A O00408 4/20 0.39
HPGD P15428 1/20 0.38
SLC6A9 P48067 1/20 0.38
FNTA P49354 2/20 0.37
FNTB P49356 2/20 0.37
OXTR P30559 1/20 0.37
PKM P14618 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303569 0.91 LMNA (0.46) KMT2AMEN1LMNAPDE2AHPGD
SCHEMBL2211106 0.87 LMNA (0.48) KMT2AMEN1LMNAHPGDFNTA
SCHEMBL1726565 0.87 KMT2A (0.42) KMT2AMEN1LMNAPDE2ASLC6A9
SCHEMBL3376238 0.86 LMNA (0.50) KMT2AMEN1LMNAHPGDPKM
SCHEMBL3378993 0.85 LMNA (0.48) KMT2AMEN1LMNAPDE2AHPGD
SCHEMBL17075498 0.84 LMNA (0.45) KMT2AMEN1LMNAHPGDFNTA
SCHEMBL304694 0.81 LMNA (0.39) KMT2AMEN1LMNAPDE2AHPGD
SCHEMBL2212915 0.80 MEN1 (0.58) KMT2AMEN1LMNAFNTAFNTB
SCHEMBL3378334 0.80 KMT2A (0.45) KMT2AMEN1LMNAHPGDPKM
SCHEMBL3376397 0.79 KMT2A (0.50) KMT2AMEN1LMNAHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US claimed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 KMT2A 386/4885MEN1 608/4885LMNA 1619/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 KMT2A 1511/4885MEN1 2747/4885LMNA 2145/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 KMT2A 386/4885MEN1 608/4885LMNA 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.